Manufacturing is a key element of the UK economy.The manufacture of pharmaceutical products accounted for 9% of the manufacturing economy in 2013. The sector has a turnover of £32 billion and invests £4.1 billion in research and development (R&D).
We have more than 1300 companies involved in medicines manufacturing. The direct gross value added per UK employee is greater than £150,000, and the sector produced £26 billion in exports in 2015.However, the sector impact has declined, with real gross value added declining by about 19% between 2008 and 2013, to £11.6 billion, in the midst of the global corporate restructuring of the industry, the ‘patent cliff’ and declining returns to R&D spending.
The MMIC aims to reverse this decline, by delivering radical improvements in productivity, through the introduction of new disruptive technologies across the pharma supply chain. This will increase UK competitiveness and productivity, and position the UK to manufacture the next generation of new small molecule drug products. This will lead to further growth in manufacturing jobs and exports in this sector.
Many potential medicines are being developed by SMEs. Establishing the MMIC will provide significant opportunities for SMEs with limited manufacturing capacity or experience to develop efficient processes and to compete globally.
The centre will form part of a co-ordinated investment in innovation, and will be integrated into the UK innovation system. It will complement and draw on other programmes of national investment delivered by Innovate UK and the research councils.
This competition is part of a £146 million investment over 4 years under the government’s Industrial Strategy Challenge Fund to support development of technologies and facilities for the manufacture of innovative medicines.
If you want help to find a project partner, contact the Knowledge Transfer Network.
If you need more information, contact the competition helpline on 0300 321 4357 or email us at email@example.com